StockNews.com Downgrades Simulations Plus (NASDAQ:SLP) to Sell

StockNews.com lowered shares of Simulations Plus (NASDAQ:SLP) from a hold rating to a sell rating in a research report report published on Monday.

Other analysts also recently issued reports about the company. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday, October 24th. KeyCorp started coverage on Simulations Plus in a report on Monday, July 29th. They set an “overweight” rating and a $47.00 price target for the company. BTIG Research decreased their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Finally, JMP Securities started coverage on Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Simulations Plus Stock Down 0.4 %

Shares of NASDAQ:SLP opened at $30.70 on Monday. The firm has a market cap of $616.15 million, a P/E ratio of 62.65 and a beta of 0.71. Simulations Plus has a 12-month low of $27.22 and a 12-month high of $51.22. The business has a fifty day simple moving average of $31.71 and a 200 day simple moving average of $39.54.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. Simulations Plus’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period last year, the company earned $0.18 EPS. As a group, equities research analysts expect that Simulations Plus will post 1.11 EPS for the current year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the sale, the director now directly owns 3,501,592 shares in the company, valued at $123,186,006.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 60,750 shares of company stock worth $1,905,655 in the last three months. Company insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

Several large investors have recently added to or reduced their stakes in SLP. nVerses Capital LLC lifted its position in shares of Simulations Plus by 1,100.0% during the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after buying an additional 1,100 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Simulations Plus during the 1st quarter worth approximately $57,000. Allspring Global Investments Holdings LLC bought a new position in shares of Simulations Plus during the 1st quarter worth approximately $70,000. Los Angeles Capital Management LLC bought a new position in shares of Simulations Plus during the 2nd quarter worth approximately $206,000. Finally, Arizona State Retirement System bought a new position in shares of Simulations Plus during the 2nd quarter worth approximately $218,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.